Niederwieser D - Search Results

1

Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.

Michael C, Bierbach U, Frenzel K, Lange T, Basara N, Niederwieser D, Mauz-Körholz C, Preiss R. Michael C, et al. Among authors: niederwieser d. Antimicrob Agents Chemother. 2010 Aug;54(8):3225-32. doi: 10.1128/AAC.01731-09. Epub 2010 Jun 14. Antimicrob Agents Chemother. 2010. PMID: 20547816 Free PMC article. Clinical Trial.

2

Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.

Deininger M, Pönisch W, Krahl R, Leiblein S, Edel E, Lange T, Fiedler F, Freund M, Franke A, Pasold R, von Grünhagen U, Herold M, Dölken G, Hoffmann FA, Uhle R, Schultze W, Steglich J, Schwarzer A, Richter P, Winkelmann C, Kettner E, Dachselt K, Subert R, Schwalbe E, Doepper J, Helbig W, Niederwieser D; East German Study Group Haematology/Oncology (OSHO). Deininger M, et al. Among authors: niederwieser d. Bone Marrow Transplant. 2001 Jun;27(11):1125-32. doi: 10.1038/sj.bmt.1703057. Bone Marrow Transplant. 2001. PMID: 11551022 Clinical Trial.

3

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.

Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF. Niederwieser D, et al. Blood. 2003 Feb 15;101(4):1620-9. doi: 10.1182/blood-2002-05-1340. Epub 2002 Oct 3. Blood. 2003. PMID: 12393457 Free article.

4

High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.

Lange T, Günther C, Köhler T, Krahl R, Musiol S, Leiblein S, Al-Ali HK, van Hoomissen I, Niederwieser D, Deininger MW. Lange T, et al. Among authors: niederwieser d. Blood. 2003 Mar 15;101(6):2152-5. doi: 10.1182/blood-2002-05-1366. Epub 2002 Oct 24. Blood. 2003. PMID: 12406906 Free article. Clinical Trial.

5

Residual disease in chronic myeloid leukemia after induction of molecular remission.

Lange T, Niederwieser DW, Deininger MW. Lange T, et al. N Engl J Med. 2003 Oct 9;349(15):1483-4. doi: 10.1056/NEJM200310093491521. N Engl J Med. 2003. PMID: 14534349 No abstract available.

6

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Müller C, Niederwieser D, Druker BJ, Deininger MW. Al-Ali HK, et al. Among authors: niederwieser d. Hematol J. 2004;5(1):55-60. doi: 10.1038/sj.thj.6200319. Hematol J. 2004. PMID: 14745431

7

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.

Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Köhler T, Krahl R, Niederwieser D, Deininger MW. Lange T, et al. Among authors: niederwieser d. Haematologica. 2004 Jan;89(1):49-57. Haematologica. 2004. PMID: 14754606

8

Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans.

Preiss R, Baumann F, Stefanovic D, Niemeyer U, Pönisch W, Niederwieser D. Preiss R, et al. Among authors: niederwieser d. Cancer Chemother Pharmacol. 2004 Jun;53(6):496-502. doi: 10.1007/s00280-003-0757-y. Epub 2004 Jan 29. Cancer Chemother Pharmacol. 2004. PMID: 15138712

9

Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias.

Niederwieser D, Gentilini C, Hegenbart U, Lange T, Becker C, Wang SY, Bartsch K, Pönisch W, Raida M, Al-Ali H. Niederwieser D, et al. Crit Rev Oncol Hematol. 2005 Nov;56(2):275-81. doi: 10.1016/j.critrevonc.2005.03.016. Epub 2005 Oct 5. Crit Rev Oncol Hematol. 2005. PMID: 16213741 Review.

10

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.

Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, Al-Ali H, Storer B, Maloney D, McSweeney P, Chauncey T, Agura E, Bruno B, Maziarz RT, Petersen F, Storb R. Hegenbart U, et al. Among authors: niederwieser d. J Clin Oncol. 2006 Jan 20;24(3):444-53. doi: 10.1200/JCO.2005.03.1765. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344316

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

629 results

Search Page

Filters